On March 26, 2025 GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, reported to have entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) (Press release, GV20 Therapeutics, MAR 26, 2025, View Source [SID1234651493]). Under this collaboration, MTPC will leverage GV20’s antibodies, which are specifically directed against novel tumor antigen targets discovered through GV20’s proprietary STEAD AI platform, to generate potentially first-in-class antibody-drug conjugates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This agreement underlines the strength of GV20’s STEAD platform in discovering novel tumor targets and human-derived antibodies." said Ying Gong, Ph.D., Chief Business Officer of GV20. "We are excited to partner with MTPC, leveraging their deep expertise in linker-payload technology and therapeutics development, to advance innovative antibody-drug conjugate (ADC) therapies against these novel targets."

Under the terms of the agreement, GV20 will receive an upfront payment and is eligible for milestone payments. MTPC will receive an exclusive right to negotiate a license to these antibodies during the collaboration term.